Skip to main content
Equibles
VRDN logo

VRDN · Viridian Therapeutics, Inc.\DE

Track VRDN — free

Use VRDN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VRDN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$22.08 +0.09 (+0.41%) At close · Aug 14
Market Cap
$2.50B
Shares
113.29M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-08-06 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
2026-06-26 Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
2026-05-27 Viridian Therapeutics to Participate in Upcoming June Investor Conferences
2026-05-07 Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
2026-05-05 Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
2026-05-05 Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
2026-05-05 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
2026-03-30 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
2026-02-26 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-01-08 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 Viridian Therapeutics Prepares for Transformational 2026
2025-12-22 Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Past events

Date Event Type
2026-06-29 Lumvoa™ (veligrotug-vvze) FDA Approval Event
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-03 Jefferies Global Healthcare Conference Conference
2026-05-05 Earnings conference call (announced in 8-K) Earnings call
2026-03-30 REVEAL-1 Phase 3 Topline Results Event
2026-03-09 Leerink Partners Global Healthcare Conference Conference
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2025-12-04 8th Annual Evercore Healthcare Conference Conference
2025-11-19 Jefferies Global Healthcare Conference in London Conference
2025-11-12 Stifel 2025 Healthcare Conference Conference
2025-06-09 Goldman Sachs Global Healthcare Conference Conference
2025-06-04 Jefferies Global Healthcare Conference Conference
2025-05-20 RBC Global Healthcare Conference Conference
2025-03-12 Leerink Global Healthcare Conference Conference
2025-03-03 TD Cowen Health Care Conference Conference
2024-12-16 THRIVE-2 Phase 3 Topline Results Event
2024-09-09 Thrive Phase 3 Topline Results Event
2024-05-08 Viridian Therapeutics First Quarter 2024 Earnings Call Earnings call
2023-12-18 Subcutaneous IGF-1R program selection Event

Source: https://investors.viridiantherapeutics.com/overview/default.aspx

Key facts CIK 1590750 CUSIP 92790C104 13F (30d) 210 filings 205 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)